Pharmacodynamics of evocalcet for secondary ... | 合法藥品大搜索

由 T Akizawa 著作 · 2020 · 被引用 8 次 — It is the newest calcimimetic in the world and was developed in Japan with the aim of resolving the issues of the upper GI effects, drug–drug interactions, and ... Read More

由 T Shigematsu 著作 · 2019 · 被引用 11 次 — Multiple doses of evocalcet reduced intact PTH levels with a concomitant decrease in serum calcium levels. Evocalcet was well tolerated in SHPT ... Read More

由 T Akizawa 著作 · 被引用 8 次 — Patients with chronic kidney disease often develop secondary hyperparathyroidism (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and ... Read More

由 M Fukagawa 著作 · 2018 · 被引用 38 次 — Keywords: Japan; cinacalcet; evocalcet; gastrointestinal; randomized controlled trial; secondary hyperparathyroidism. Copyright © 2018 ... Read More

由 K Yokoyama 著作 · 2019 · 被引用 15 次 — Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), and as the disease progresses SHPT is ... Read More

由 K Yokoyama 著作 · 2019 · 被引用 15 次 — Evocalcet is a novel calcimimetic developed as an equally efficacious, but more tolerable, alternative to the currently available ... Read More

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism. It acts as a calcium-sensing receptor agonist. Read More

Evocalcet is an orally available calcium receptor (CaR) modulator, with potential calcimimetic activity. Upon administration, evocalcet allosterically binds ... Read More

由 T Akizawa 著作 · 2020 · 被引用 8 次 — It is the newest calcimimetic in the world and was developed in Japan with the aim of resolving the issues of the upper GI effects, drug–drug ... Read More

由 T Shigematsu 著作 · 2018 · 被引用 10 次 — Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan ... Read More